Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | CDK4 | P11802 | 2/20 | 0.50 |
| ▸ | CCND1 | P24385 | 2/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.50 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502999 | 1.00 | MAOB (0.54) | MAOBACHECDK4CCND1CCNB2 | |
| SCHEMBL5087354 | 0.87 | MAOB (0.53) | MAOBACHECDK4CCND1CCNB2 | |
| SCHEMBL13577008 | 0.83 | ACHE (0.49) | MAOBACHECDK4CCND1CCNB2 | |
| SCHEMBL20526908 | 0.81 | MAOB (0.56) | MAOBALOX5 | |
| SCHEMBL18702902 | 0.79 | MAOB (0.49) | MAOBACHECDK4CCND1CCNB2 | |
| SCHEMBL21340421 | 0.78 | MAOB (0.61) | MAOBACHECDK4CCND1CCNB2 | |
| SCHEMBL5090936 | 0.78 | MAOB (0.48) | MAOBACHESLC26A4FFAR1KMT2A | |
| SCHEMBL4638503 | 0.78 | MAOB (0.60) | MAOBACHECDK4CCND1CCNB2 | |
| SCHEMBL31172168 | 0.78 | MAOB (0.60) | MAOBACHECDK4CCND1CCNB2 | |
| SCHEMBL13577234 | 0.77 | CACNA1C (0.48) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-07-21 | — | — | US | disclosed |
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3359536-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2018-10-11 | — | — | US | disclosed |
| WO-2017062581-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | MAOB 4409/4885ACHE 3377/4885CDK4 3310/4885 |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | MAOB 4409/4885ACHE 3377/4885CDK4 3310/4885 |
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | MAOB 4409/4885ACHE 3377/4885CDK4 3310/4885 |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | MAOB 4409/4885ACHE 3377/4885CDK4 3310/4885 |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | MAOB 4409/4885ACHE 3377/4885CDK4 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.